BridgeBio Pharma, Inc. (BBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US10806X1028
BridgeBio Pharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 502.08 m USD |
| Gross profit | 481.11 m USD |
| Operating income | -523.41 m USD |
| EBIT | -699.25 m USD |
| Net income | -724.93 m USD |
| Diluted EPS – continuing operations | -3.78 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
More stocks
- MANHATTAN ASSOCIATES INC (MANH)
- Tbea Co Ltd (600089.SS)
- SK Holdings 1p Pref (03473K.KS)
- Carlyle Group Inc. (CG)
- INNIO N.V. Ordinary Shares (INIO)
- Baxter International (BAX)
- Textron (TXT)
- Wise PLC (WISE.L)
- Aegon NV (AGN.AS)
- GEA Group (G1A.DE)
- Sichuan Chuantou Energy Co Ltd (600674.SS)
- DT Midstream, Inc. (DTM)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.